- Home
- ATXS vs GNE Comparison
ATXS vs GNE Comparison
Compare ATXS & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- GNE
- Stock Information
- Founded
- ATXS 2008
- GNE 2011
- Country
- ATXS United States
- GNE United States
- Employees
- ATXS N/A
- GNE N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- GNE Power Generation
- Sector
- ATXS Health Care
- GNE Utilities
- Exchange
- ATXS Nasdaq
- GNE Nasdaq
- Market Cap
- ATXS 401.2M
- GNE 402.0M
- IPO Year
- ATXS 2015
- GNE N/A
- Fundamental
- Price
- ATXS $4.76
- GNE $21.16
- Analyst Decision
- ATXS Strong Buy
- GNE
- Analyst Count
- ATXS 7
- GNE 0
- Target Price
- ATXS $32.43
- GNE N/A
- AVG Volume (30 Days)
- ATXS 625.9K
- GNE 128.1K
- Earning Date
- ATXS 05-13-2025
- GNE 05-06-2025
- Dividend Yield
- ATXS N/A
- GNE 1.42%
- EPS Growth
- ATXS N/A
- GNE 10.33
- EPS
- ATXS N/A
- GNE 0.55
- Revenue
- ATXS N/A
- GNE $442,321,000.00
- Revenue This Year
- ATXS N/A
- GNE N/A
- Revenue Next Year
- ATXS N/A
- GNE N/A
- P/E Ratio
- ATXS N/A
- GNE $32.30
- Revenue Growth
- ATXS N/A
- GNE N/A
- 52 Week Low
- ATXS $3.56
- GNE $13.05
- 52 Week High
- ATXS $12.92
- GNE $21.29
- Technical
- Relative Strength Index (RSI)
- ATXS 54.89
- GNE 79.95
- Support Level
- ATXS $3.83
- GNE $18.38
- Resistance Level
- ATXS $4.98
- GNE $21.06
- Average True Range (ATR)
- ATXS 0.45
- GNE 0.84
- MACD
- ATXS 0.11
- GNE 0.27
- Stochastic Oscillator
- ATXS 82.93
- GNE 97.34
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.